AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02585700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine, split inactivated
Description: Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen's eggs, and inactivated with beta-propiolactone.
Study NCT02585700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL of phosphate buffered saline
Study NCT01421706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sibutramine-clopidogrel
Description: Sibutramine-clopidogrel
Study NCT01421706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sibutramine-Clarithromycin
Description: sibutramine-Clarithromycin
Study NCT01619826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 9-month afterschool program designed to increase physical activity and aerobic fitness.
Study NCT01619826 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Activity
Description: Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
Study NCT04276883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual film containing Dexmedetomidine (BXCL501)
Description: Sublingual film containing Dexmedetomidine (BXCL501)
Study NCT04276883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Film
Description: Placebo Film for BXCL501
Study NCT02820922 — intervention group
Intervention type: PROCEDURE
Intervention: Orthopedic
Description: anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
Study NCT00450307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 3F8
Study NCT00450307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT02009800 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Description: One dose of Gardasil administered in the intervention group
Study NCT03110315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: See detailed information in associated Arm Description.
Study NCT03110315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic suvorexant 10 mg tablet.
Study NCT02166697 — intervention group
Intervention type: DRUG
Intervention: candesartan cilexetil
Description: candesartan cilexetil tablets
Study NCT06277193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: valuation of balance status, fear of falling and risk of falling in patients non-sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
Study NCT06277193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of balance status, fear of falling and risk of falling in patients with probable sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
Study NCT06277193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of balance status, fear of falling and risk of falling in patients with sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
Study NCT06277193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of balance status, fear of falling and risk of falling in patients with severe sarcopenia.
Description: Daily living activities, frailty, physical performance, balance status, risk of falling, fear of falling, nutritional status, and mental status were evaluated with various scales.
Study NCT00527800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
Study NCT00527800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
Study NCT00527800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Description: Once daily dosing according to weight based guidelines
Study NCT01911195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISOFLURANE- Experimental Arm
Description: The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
Study NCT01911195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Cognitive Testing
Description: The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
Study NCT04333706 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Capecitabine 1000 mg BID
Study NCT04333706 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sarilumab 150mg or 200 mg plus Capecitabine
Description: Sarilumab 150mg or 200 mg plus Capecitabine 1000 mg BID
Study NCT04333706 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sarilumab 150mg plus Capecitabine
Description: Dose escalation schedule of sarilumab. The starting dose for sarilumab is 150 mg SQ every 21 days, given 3 days prior to the first 4 of 8 cycles of capecitabine 1000 mg BID.
Study NCT04442776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D-AIP
Description: Intervention on change motivation, insight, medication adherence, drug consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety
Study NCT01747603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized LPTB clinic
Description: 50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
Study NCT04488575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered monoclonal microbe
Study NCT04488575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study NCT01595503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS with fMRI-based targeting
Description: Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
Study NCT01595503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS with landmark-based targeting
Description: Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
Study NCT01672190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Therapy Program
Study NCT04812756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-2-It - text messaging program
Description: participants received a pedometer and text messages to motivate them to increase walking daily for a period of 12 weeks.
Study NCT01860248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Description: The Vapocoolant spray containing alkane is applied for 20 seconds.
Study NCT01860248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water spray
Description: This spray is covered so the patient and the investigator can not find the spray type out.
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK 257049
Description: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™ HepB/Hib
Description: GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™ HepB/Hib
Description: GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rouvax™
Description: Aventis Pasteur's attenuated measles vaccine.
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rouvax™
Description: Aventis Pasteur's attenuated measles vaccine.
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stamaril™
Description: Aventis Pasteur's attenuated yellow fever vaccine.
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stamaril™
Description: Aventis Pasteur's attenuated yellow fever vaccine.
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: GSK Biologicals' oral polio virus vaccine
Study NCT00436007 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: GSK Biologicals' oral polio virus vaccine
Study NCT01106963 — intervention group
Intervention type: PROCEDURE
Intervention: Tibial intramedullary nailing
Description: Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
Study NCT04622709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide (loop diuretic) Tablets
Description: Open label dose escalation study of furosemide in people receiving maintenance hemodialysis. Participants will take furosemide oral tablets twice daily for 18 weeks. Doses will be titrated every 2 weeks for 6 weeks if safe, effective, tolerated, and accepted by the participant. First 2 weeks of the study: participants not taking oral furosemide at enrollment will take 80mg furosemide twice daily, those taking oral furosemide at enrollment will stay on their prescribed dose, and those taking another loop diuretic at enrollment will discontinue their prescription and take an equivalent oral furosemide dose. At week 4: dose escalation if tolerated (from 80mg to 120mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd \& 3rd groups). At week 6: dose escalation if tolerated (from 120mg to 160mg twice daily for the 1st group, and a 50% increased dose not >320mg/day for the 2nd \& 3rd groups). Final 12 weeks: all participants will take the maximum tolerated dose.
Study NCT04553575 — intervention group
Intervention type: BIOLOGICAL
Intervention: serology
Description: biological blood samples withdrawn at 6, 12 and 24 months
Study NCT00532337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-5334
Description: Placebo - 24/mos.
Study NCT00532337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 100mg QD /24 months
Study NCT00532337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 50mg BID /24 mos.
Study NCT00532337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5334
Description: 300mg QD /24 mos.
Study NCT00532337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONO-5334
Description: Alendronate 70mg once weekly / 24 mos
Study NCT02684552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: Training on treadmill with Non invasive ventilation
Study NCT02684552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Training on treadmill with oxygen
Study NCT04173936 — intervention group
Intervention type: BEHAVIORAL
Intervention: tai chi
Description: 12-week community-based tai chi program
Study NCT00537147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WN/DEN4delta30 vaccine
Description: Live attenuated WN/DEN4delta30 vaccine (one of two doses)
Study NCT00537147 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for WN/DEN4delta30 vaccine
Study NCT03712722 — intervention group
Intervention type: OTHER
Intervention: Faecal microbiota transplantation (FMT)
Description: FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
Study NCT03056248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
Study NCT03056248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
Study NCT01941095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT01941095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT01941095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT01941095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT01941095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT01941095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
Study NCT01941095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
Study NCT02852564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethacrynic Acid
Description: One oral dose at 50 mg prior to bladder tumor removal surgery
Study NCT03536338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Stimulation
Description: transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
Study NCT03536338 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sit-to-stand Training
Description: Rehabilitation of standing from a chair using the Keiser Rack
Study NCT03536338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit-to-stand Training
Description: Rehabilitation of standing from a chair using the Keiser Rack
Study NCT03080649 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: excavated with rotary bur
Description: One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
Study NCT03080649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
Study NCT02080923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
Study NCT03991156 — intervention group
Intervention type: DEVICE
Intervention: Audio-Visual Assisted Therapeutic Ambience in Radiotherapy
Description: Audio Visual System
Study NCT03991156 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Survey, PedsQL3.0
Description: Quality of life survey using the PedsQL 3.0 Cancer Module
Study NCT03991156 — intervention group
Intervention type: OTHER
Intervention: Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)
Description: Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).\[24\] is a survey to measure anxiety
Study NCT02834000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO rapid™ CNAP monitoring
Description: LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
Study NCT00154180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated equine estrogens 0.45 mg/day
Description: Pill, 1 pill taken daily each month for the study duration
Study NCT00154180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal estradiol, 50 mcg/day
Description: Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
Study NCT00154180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone, 200 mg/day x 12 d/month
Description: capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
Study NCT00154180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CEE , progesterone, estradiol patch or placebo for each
Description: CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
Study NCT00154180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEE, progesterone, transdermal patch or the placebo
Description: CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
Study NCT00154180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CEE, progesterone, transdermal patch or the placebo
Description: CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
Study NCT02295878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment capsule containing seaweed extract (treatment)
Description: 400mg capsule containing seaweed extract (treatment)
Study NCT02295878 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01775319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biofortified wheat
Description: Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
Study NCT01775319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified wheat
Description: Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
Study NCT01775319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02361047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Coaching Program
Description: Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
Study NCT01434121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
Study NCT01434121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo